Compare British American Tobacco PLC (BTI) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Incyte Corporation — how do they compare? British American Tobacco PLC trades at $56.92 (market cap $122.36B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: British American Tobacco PLC is far larger — about 5× Incyte Corporation's market cap, and British American Tobacco PLC pays a 5.88% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BTI | INCY | |
|---|---|---|
Market Cap | $122.36B | $24.54B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $129.93 |
52-Week Low | $50.39 | $81.61 |
Enterprise Value | $166.31B | $20.04B |
Dividend Yield | 5.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $55.9, down 2.02% today, with a bearish technical signal overall despite bullish oscillators. The company reported Q2 2026 EPS of $2.25, beating expectations, and maintains strong profitability with a 24.99% net income margin. Recent news highlights its strategic tech partnership with ITC Infotech and workforce restructuring to cut costs.
Outlook is mixed: strong fundamentals and a 66.67% analyst buy rating support upside, but technical weakness and regulatory risks pose challenges. The stock offers value with a P/E of 14.48 and dividend yield, yet faces headwinds from declining combustibles and debt levels.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
